Itopride as a Potential Drug Against Cancer (Breast and Prostate), by Repurposing Determined Through AI

Breast and prostate cancer continue with high prevalence inside the top five. According to the global cancer statistics published by the American Cancer Society (2022), with approximately 20 million new cancer cases and almost 10 million related deaths each year, the need for more therapeutic options against cancer is evident. Therefore, proposing or repurposing drugs that can contribute to current treatments will be relevant in the healthcare sector. In recent years, following the COVID-19 pandemic, drug repurposing has increased, further amplified by the use of artificial intelligence (AI). In this way, using AI, we propose the drug Itopride as a potential antiproliferative agent in cancer. This effect was determined through in silico and in vitro assays. Therefore, through AI and drug repurposing, we propose Itopride as a potential adjuvant against prostate and breast cancer. This is justified by the cytotoxic and antiproliferative effects of Itopride observed in vitro cultures. Currently, Itopride is available in several countries and is primarily used as a prokinetic agent and for functional dyspepsia.